1. Gu R, Cao J, Wei S, Gong X, Wang Y, Mi Y, Zhang J, Qiu S, Rao Q, Wang M, Wei H, Wang J. Evaluation of pretreatment telomere length as a prognostic marker in intermediate-risk acute myeloid leukemia. Int J Lab Hematol. 2021 Dec;43(6):1510-1515. doi: 10.1111/ijlh.13665. Epub 2021 Jul 21. PMID: 34288423.
2. Wei H, Liu X, Wang Y, Lin D, Zhou C, Liu B, Qiu S, Gu R, Li Y, Wei S, Gong B, Liu K, Gong X, Liu Y, Zhang G, Fang Q, Zhang J, Jin J, Ma Y, Mi Y, Wang J. The Optimized Clinical Application of Minimal Residual Disease in Acute Myeloid Leukemia with RUNX1-RUNX1T1. Exp Hematol. 2021 Apr;96:63-72.e3. doi:10.1016/j.exphem.2021.01.007. Epub 2021 Jan 29. PMID: 33524443.
3. Chen Y, Liu Q, Shi Z, Zhang G, Wang M, Mi Y, Wei H, Wang J. Identification and lineage restriction analyses of preleukemia cells in a sporadic biallelic CEBPA mutated acute myeloid leukemia patient. Int J Lab Hematol. 2020 Dec 23. doi: 10.1111/ijlh.13449. Epub ahead of print. PMID: 33369101
4. Wei H, Zhou C, Lin D, Liu B, Li Y, Zhao X, Wei S, Gong B, Liu K, Gong X, Liu Y, Zhang G, Chen J, Zhang J, Jin J, Qiu S, Gu R, Wang Y, Mi Y, Wang J. Benefit of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia. Haematologica. 2020 Sep 28;106(5):1491-1495. doi: 10.3324/haematol.2020.267526. PMID: 33054134; PMCID: PMC8094090.
5. Yan D, Wei H, Lai X, Ge Y, Xu S, Meng J, Wen T, Liu J, Zhang W, Wang J, Xu H. Co-delivery of homoharringtonine and doxorubicin boosts therapeutic efficacy of refractory acute myeloid leukemia. J Control Release. 2020 Sep 17;327:766-778. (并列第一作者)
6. Wei H, Wang Y, Gale RP, Lin D, Zhou C, Liu B, Qiu S, Gu R, Li Y, Zhao X, Wei S, Gong B, Liu K, Gong X, Liu Y, Zhang G, Song Z, Wang Y, Li W, Mi Y, Wang J. Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia. Clin Cancer Res. 2020 Jul 1;26(13):3154-3161.
7. Gu R, Yang X, Wei H. Molecular landscape and targeted therapy of acute myeloid leukemia. Biomark Res. 2018 Nov 8;6:32.
8. Wei H, Wang Y, Zhou C, Lin D, Liu B, Liu K, Qiu S, Gong B, Li Y, Zhang G, Wei S, Gong X, Liu Y, Zhao X, Gu R, Mi Y, Wang J. Distinct genetic alterationprofiles of acute myeloid leukemia between Caucasian and Eastern Asianpopulation. J HematolOncol. 2018 Feb 10;11(1):18.
9. Wei H, Xiang L, Wayne AS, Chertov O, FitzGerald DJ, Bera TK, Pastan I. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proc Natl Acad Sci U S A. 109(18):6898-6903.2012. (影响因子:9.681)
10. Wei H,Bera TK, Wayne AS, Xiang L, Colantonio S, Chertov O, Pastan I. A modified form ofdiphthamidecausesimmunotoxinresistance in a lymphomacelllinewith a deletionofthe WDR85 gene. J Biol Chem. 2013; 288(17): 12305-12312。
11. Wei H, Liu X, Xiong X, Wang Y, Rao Q, Wang M, Wang J. AML1-ETO interactswith Sp1 andantagonizes Sp1 transactivitythrough RUNT domain. FEBS Lett. 2008; 582(15): 2167-2172。